
TY  - JOUR
TI  - ASBMR 22nd annual meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 15
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650150102
DO  - doi:10.1002/jbmr.5650150102
SP  - S1
EP  - S584
PY  - 2000
ER  - 

TY  - JOUR
TI  - 8th European Congress on Epileptology,  Berlin, Germany, 21 – 25 September 2008
JO  - Epilepsia
VL  - 50
IS  - s4
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1167.2009.02063.x
DO  - doi:10.1111/j.1528-1167.2009.02063.x
SP  - 1
EP  - 261
PY  - 2009
ER  - 

TY  - JOUR
TI  - 2016 ACR/ARHP Annual Meeting Abstract Supplement
JO  - Arthritis & Rheumatology
JA  - Arthritis & Rheumatology
VL  - 68
IS  - S10
SN  - 2326-5191
UR  - https://doi.org/10.1002/art.39977
DO  - doi:10.1002/art.39977
SP  - 1
EP  - 4550
PY  - 2016
AB  - For a searchable version of these abstracts, please visit www.acrabstracts.org.
ER  - 

TY  - JOUR
TI  - Abstract of 30th Regional Congress of the ISBT
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 114
IS  - S2
SN  - 0042-9007
UR  - https://doi.org/10.1111/vox.12847
DO  - doi:10.1111/vox.12847
SP  - 5
EP  - 135
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts from the 4th International Congress of the World Apheresis Association
JO  - Artificial Organs
VL  - 17
IS  - 1
SN  - 0160-564X
UR  - https://doi.org/10.1111/j.1525-1594.1993.tb00387.x
DO  - doi:10.1111/j.1525-1594.1993.tb00387.x
SP  - 47
EP  - 70
PY  - 1993
ER  - 

TY  - JOUR
TI  - Poster Presentations A
JO  - Pain Practice
VL  - 9
IS  - s1
SN  - 1530-7085
UR  - https://doi.org/10.1111/j.1533-2500.2009.00266.x
DO  - doi:10.1111/j.1533-2500.2009.00266.x
SP  - 19
EP  - 93
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - HPB
JA  - HPB
VL  - 15
IS  - S1
SN  - 1365-182X
UR  - https://doi.org/10.1111/hpb.12048
DO  - doi:10.1111/hpb.12048
SP  - 1
EP  - 87
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - HPB
VL  - 9
IS  - s1
SN  - 1365-182X
UR  - https://doi.org/10.1080/16515320701258846
DO  - doi:10.1080/16515320701258846
SP  - 36
EP  - 110
PY  - 2007
ER  - 

TY  - JOUR
TI  - American Society for Laser Medicine and Surgery thirteenth annual meeting New Orleans, Louisiana abstracts
JO  - Lasers in Surgery and Medicine
JA  - Lasers Surg. Med.
VL  - 13
IS  - S5
SN  - 0196-8092
UR  - https://doi.org/10.1002/lsm.1900130702
DO  - doi:10.1002/lsm.1900130702
SP  - 1
EP  - 77
PY  - 1993
ER  - 

TY  - JOUR
TI  - Abstracts from the 33rd Annual Scientific Meeting of the Transplantation Society of Australia and new Zealand
JO  - Immunology & Cell Biology
JA  - Immunol Cell Biol
VL  - 93
IS  - 9
SN  - 0818-9641
UR  - https://doi.org/10.1038/icb.2015.75
DO  - doi:10.1038/icb.2015.75
SP  - A1
EP  - A35
PY  - 2015
ER  - 

TY  - JOUR
TI  - Moderated Poster Presentations
JO  - International Journal of Urology
VL  - 13
IS  - s1
SN  - 0919-8172
UR  - https://doi.org/10.1111/j.1442-2042.2006.01622.x
DO  - doi:10.1111/j.1442-2042.2006.01622.x
SP  - A23
EP  - A62
PY  - 2006
ER  - 

TY  - JOUR
TI  - 2013 ACVIM Forum Research Abstracts Program
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 27
IS  - 3
SN  - 0891-6640
UR  - https://doi.org/10.1111/jvim.12100
DO  - doi:10.1111/jvim.12100
SP  - 604
EP  - 756
PY  - 2013
ER  - 

TY  - JOUR
TI  - Research Abstract Program of the 2009 ACVIM Forum & Canadian Veterinary Medical Association Convention
JO  - Journal of Veterinary Internal Medicine
VL  - 23
IS  - 3
SN  - 0891-6640
UR  - https://doi.org/10.1111/j.1939-1676.2009.0316.x
DO  - doi:10.1111/j.1939-1676.2009.0316.x
SP  - 673
EP  - 786
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstracts (Continue in Part XII)
JO  - Proceedings of the International Society for Magnetic Resonance in Medicine
JA  - Proc. Soc. Magn. Reson. Med.
VL  - 1997
IS  - S1
SN  - 1065-9889
UR  - https://doi.org/10.1002/mrmp.22419970112
DO  - doi:10.1002/mrmp.22419970112
SP  - 551
EP  - 600
PY  - 1997
ER  - 

TY  - JOUR
TI  - Thursday, 28 July 2011
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - s2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2011.04380_4.x
DO  - doi:10.1111/j.1538-7836.2011.04380_4.x
SP  - 712
EP  - 959
PY  - 2011
ER  - 

TY  - JOUR
TI  - Burns and Plastic Surgery Section
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 98
IS  - 6
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.7508
DO  - doi:10.1002/bjs.7508
SP  - e11
EP  - e17
PY  - 2011
AB  - Abstract The BBA joined the Society of Academic and Research Surgery for their Annual Meeting on 6 January 2010 at the Royal Free Hospital. Copyright ? 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
TI  - SUBJECT INDEX
JO  - Annals of the New York Academy of Sciences
VL  - 449
IS  - 1
SN  - 0077-8923
UR  - https://doi.org/10.1111/j.1749-6632.1985.tb49542.x
DO  - doi:10.1111/j.1749-6632.1985.tb49542.x
SP  - 101
EP  - 228
PY  - 1985
ER  - 

TY  - JOUR
AU  - Baldrick, Paul
AU  - Richardson, Derek
AU  - Wheeler, Alan W.
AU  - Woroniecki, Stefan R.
TI  - Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy
JO  - Journal of Applied Toxicology
JA  - J. Appl. Toxicol.
VL  - 24
IS  - 4
SN  - 0260-437X
UR  - https://doi.org/10.1002/jat.981
DO  - doi:10.1002/jat.981
SP  - 261
EP  - 268
KW  - grass pollen
KW  - allergy vaccines
KW  - Pollinex® Quattro
KW  - MPL® adjuvant
KW  - toxicity studies
PY  - 2004
AB  - Abstract A novel allergy vaccine (Pollinex? Quattro) has been developed for the prevention or relief of allergic symptoms caused by a variety of pollens. Within this range, the grass pollen allergy vaccine contains extracts of 12 grass pollens and rye cereal (all chemically modi?ed by glutaraldehyde) that are adsorbed onto l-tyrosine with addition of the immunostimulatory adjuvant monophosphoryl lipid A (MPL?). A speci?c preclinical safety testing strategy was developed to support clinical use, comprising single-dose toxicity, repeat-dose toxicity and local tolerance studies. Dose levels of up to 0.5 ml per animal (mouse) and up to 1.0 ml per animal (rat and rabbit) were used with vaccines containing 2000 or 12 000 standardized units (SU) ml?1 of grass pollen allergoids, 50 µg ml?1 of MPL? adjuvant and 20 mg ml?1 of tyrosine. Overall, the product showed no toxicological ?ndings of signi?cance at levels greatly in excess of those proposed for clinical use. A not unexpected, but relatively minor, immunostimulatory effect was seen following repeated dosing (once weekly for 3 weeks) at 1.0 ml per rat. Copyright ? 2004 John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
AU  - Weiner, Michael W.
AU  - Veitch, Dallas P.
AU  - Aisen, Paul S.
AU  - Beckett, Laurel A.
AU  - Cairns, Nigel J.
AU  - Green, Robert C.
AU  - Harvey, Danielle
AU  - Jack Jr., Clifford R.
AU  - Jagust, William
AU  - Morris, John C.
AU  - Petersen, Ronald C.
AU  - Saykin, Andrew J.
AU  - Shaw, Leslie M.
AU  - Toga, Arthur W.
AU  - Trojanowski, John Q.
AU  - Alzheimer's Disease Neuroimaging Initiative
TI  - Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
JO  - Alzheimer's & Dementia
JA  - Alzheimer's & Dementia
VL  - 13
IS  - 4
SN  - 1552-5260
UR  - https://doi.org/10.1016/j.jalz.2016.11.007
DO  - doi:10.1016/j.jalz.2016.11.007
SP  - e1
EP  - e85
KW  - Alzheimer's disease
KW  - Mild cognitive impairment
KW  - Amyloid
KW  - Tau
KW  - Biomarker
KW  - Disease progression
PY  - 2017
AB  - Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers. This review summarizes the over 400 publications using ADNI data during 2014 and 2015. Methods We used standard searches to find publications using ADNI data. Results (1) Structural and functional changes, including subtle changes to hippocampal shape and texture, atrophy in areas outside of hippocampus, and disruption to functional networks, are detectable in presymptomatic subjects before hippocampal atrophy; (2) In subjects with abnormal ?-amyloid deposition (A?+), biomarkers become abnormal in the order predicted by the amyloid cascade hypothesis; (3) Cognitive decline is more closely linked to tau than A? deposition; (4) Cerebrovascular risk factors may interact with A? to increase white-matter (WM) abnormalities which may accelerate Alzheimer's disease (AD) progression in conjunction with tau abnormalities; (5) Different patterns of atrophy are associated with impairment of memory and executive function and may underlie psychiatric symptoms; (6) Structural, functional, and metabolic network connectivities are disrupted as AD progresses. Models of prion-like spreading of A? pathology along WM tracts predict known patterns of cortical A? deposition and declines in glucose metabolism; (7) New AD risk and protective gene loci have been identified using biologically informed approaches; (8) Cognitively normal and mild cognitive impairment (MCI) subjects are heterogeneous and include groups typified not only by ?classic? AD pathology but also by normal biomarkers, accelerated decline, and suspected non-Alzheimer's pathology; (9) Selection of subjects at risk of imminent decline on the basis of one or more pathologies improves the power of clinical trials; (10) Sensitivity of cognitive outcome measures to early changes in cognition has been improved and surrogate outcome measures using longitudinal structural magnetic resonance imaging may further reduce clinical trial cost and duration; (11) Advances in machine learning techniques such as neural networks have improved diagnostic and prognostic accuracy especially in challenges involving MCI subjects; and (12) Network connectivity measures and genetic variants show promise in multimodal classification and some classifiers using single modalities are rivaling multimodal classifiers. Discussion Taken together, these studies fundamentally deepen our understanding of AD progression and its underlying genetic basis, which in turn informs and improves clinical trial design.
ER  - 

AU  - Morgan, Shanna
AU  - McCullough, Jeffrey
C7  - pp. 388-406
TI  - Therapeutic apheresis
SN  - 9781119012993
UR  - https://doi.org/10.1002/9781119013020.ch33
DO  - doi:10.1002/9781119013020.ch33
SP  - 388-406
KW  - coagulopathy
KW  - hyperviscosity
KW  - immunoglobulin
KW  - nonplasma replacement solutions
KW  - plasma exchange
KW  - renal failure
KW  - therapeutic apheresis
PY  - 2017
AB  - Summary Therapeutic apheresis is one of the few areas of Transfusion Medicine involving direct patient care. This can involve exchange transfusions of plasma or red cells, therapeutic cytoreduction in clinical situations with abnormal accumulations of blood cells, usually myeloid or platelets, selective removal of offending molecules such as lipoproteins, or treatment of mononuclear cells with photochemical technology to treat immune diseases. Plasma exchange is used in a variety of immune diseases while red cell exchange is almost exclusively done in patients with sickle cell disease. The mechanism of action of photopheresis in not well understood but it is used in one lymphoid malignance, graft rejection and GVHD. The processes of therapeutic apheresis can be complex especially since some of the patients are quite ill. This chapter reviews the techniques and the clinical use of these procedures.
ER  - 
